Geneva Capital Management Increases Stake in Vericel Corporation

Biotechnology company sees boost in institutional investment

Mar. 11, 2026 at 11:40am

Got story updates? Submit your updates here. ›

Geneva Capital Management LLC has increased its holdings in Vericel Corporation (NASDAQ:VCEL) by 9.0% in the third quarter, according to a recent 13F filing with the Securities and Exchange Commission. The fund now owns 1,946,305 shares of the biotechnology company's stock, representing a 3.85% stake worth $61.25 million.

Why it matters

The increase in institutional investment from a major player like Geneva Capital Management signals confidence in Vericel's long-term growth potential. As a biotech firm focused on regenerative medicine, Vericel's specialized cell-based therapies could see rising demand as the field continues to advance.

The details

Geneva Capital Management acquired an additional 161,378 shares of Vericel in the third quarter, bringing its total position to nearly 2 million shares. Other large investors, including BNP Paribas Financial Markets, Swiss National Bank, WINTON GROUP Ltd, and Rhenman & Partners Asset Management AB, also increased their stakes in Vericel during the same period.

  • Geneva Capital Management filed its 13F report for the third quarter of 2026.

The players

Geneva Capital Management LLC

An investment management firm based in Geneva, Illinois that specializes in managing equity portfolios for institutional and individual clients.

Vericel Corporation

A biotechnology company that develops and commercializes cell-based therapies for patients with severe diseases and conditions, focusing on regenerative medicine.

Got photos? Submit your photos here. ›

The takeaway

The increased investment from Geneva Capital Management underscores the growing institutional interest in Vericel's specialized cell-based therapies, which could signal a positive outlook for the company's future growth and development in the regenerative medicine space.